Ganoderic Acid A Enhances Tumor Suppression Function of Oxaliplatin via Inducing the Cytotoxicity of T Cells
Zhichao Song1, Chunhui Wang2, Fei Ding3
1Department of Anorectal Surgery, The First Hospital of Zibo City, No. 4 Emeishandong Road, Zibo 255200, Shandong, China.
Background:
Various natural products have been demonstrated for their anti-tumor activities. As a natural triterpenoid, the effects of ganoderic acid A on oxaliplatin chemotherapy for cancer treatment remain unclear.
Methods:
A xenograft mouse model of colon cancer was constructed using the HT-29 cells. Ganoderic acid A was intravenously administered with or without oxaliplatin. The CCK-8 method was performed to assess cell viability. Flow cytometry was used to determine cell apoptosis and subtyping of T cells. Cytotoxicity of the T cells was assayed using a lymphocyte-tumor co-culture system in vitro.
Results:
Ganoderic acid A enhanced tumor suppression of oxaliplatin in the xenograft model, while single administration showed no obvious anti-tumor effect. Ganoderic acid A didn't affect cell proliferation and apoptosis of HT-29 cells treated by oxaliplatin in vitro. Additionally, ganoderic acid A co-administered with oxaliplatin didn't impact T cell subtyping in the xenograft model. Cytotoxicity of T cells in co-administered mice was remarkably enhanced compared with oxaliplatin-treated mice.
Conclusion:
Our findings reveal that ganoderic acid A synergistically enhances tumor suppression of oxaliplatin possibly via increasing the cytotoxicity of T cells.
Insights
Ganoderic acid A boosts oxaliplatin chemotherapy for colon cancer by enhancing T cell activity. This natural triterpenoid improves tumor suppression when combined with oxaliplatin, offering a potential synergistic cancer treatment.
Area of Science:
- Oncology
- Immunology
- Natural Products Chemistry
Background:
- Natural products show anti-tumor potential.
- Ganoderic acid A (a triterpenoid) effects on oxaliplatin chemotherapy are unknown.
Purpose of the Study:
- To investigate ganoderic acid A's impact on oxaliplatin chemotherapy for colon cancer.
- To explore the mechanisms behind ganoderic acid A's effects.
Main Methods:
- Colon cancer xenograft mouse model (HT-29 cells).
- Intravenous administration of ganoderic acid A with/without oxaliplatin.
- Assessed cell viability (CCK-8), apoptosis, T cell subtyping (flow cytometry), and T cell cytotoxicity (in vitro co-culture).
Main Results:
- Ganoderic acid A enhanced oxaliplatin's tumor suppression in vivo; no effect alone.
- Ganoderic acid A did not affect HT-29 cell proliferation or apoptosis in vitro.
- T cell cytotoxicity was significantly enhanced in mice receiving both ganoderic acid A and oxaliplatin.
Conclusions:
- Ganoderic acid A synergistically enhances oxaliplatin's anti-tumor effects.
- The synergy may be mediated by increased T cell cytotoxicity.
Related Concept Videos
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:15Drugs that Stabilize Microtubules
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...